vs
PEOPLES BANCORP OF NORTH CAROLINA INC（PEBK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是PEOPLES BANCORP OF NORTH CAROLINA INC的1.4倍（$30.3M vs $21.5M），PEOPLES BANCORP OF NORTH CAROLINA INC净利率更高（30.8% vs -221.3%，领先252.2%），REGENXBIO Inc.同比增速更快（43.0% vs 5.6%），PEOPLES BANCORP OF NORTH CAROLINA INC自由现金流更多（$20.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 4.2%）
美国北卡罗来纳州人民银行控股公司是一家区域性银行控股企业，总部位于美国北卡罗来纳州，主要面向当地居民、中小企业及社区机构提供个人与商业银行服务，涵盖存款账户、各类贷款、抵押业务及财富管理解决方案等。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PEBK vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$21.5M
营收增速更快
RGNX
高出37.4%
5.6%
净利率更高
PEBK
高出252.2%
-221.3%
自由现金流更多
PEBK
多$72.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
4.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.5M | $30.3M |
| 净利润 | $6.6M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 40.7% | -190.0% |
| 净利率 | 30.8% | -221.3% |
| 营收同比 | 5.6% | 43.0% |
| 净利润同比 | 86.4% | -31.2% |
| 每股收益（稀释后） | $1.21 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PEBKRGNX
| Q4 25 | $21.5M | $30.3M | ||
| Q3 25 | $21.4M | $29.7M | ||
| Q2 25 | $20.7M | $21.4M | ||
| Q1 25 | $20.0M | $89.0M | ||
| Q4 24 | $20.4M | $21.2M | ||
| Q3 24 | $20.5M | $24.2M | ||
| Q2 24 | $20.1M | $22.3M | ||
| Q1 24 | $19.8M | $15.6M |
净利润PEBKRGNX
| Q4 25 | $6.6M | $-67.1M | ||
| Q3 25 | $3.7M | $-61.9M | ||
| Q2 25 | $5.2M | $-70.9M | ||
| Q1 25 | $4.3M | $6.1M | ||
| Q4 24 | $3.6M | $-51.2M | ||
| Q3 24 | $4.0M | $-59.6M | ||
| Q2 24 | $4.9M | $-53.0M | ||
| Q1 24 | $3.9M | $-63.3M |
毛利率PEBKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率PEBKRGNX
| Q4 25 | 40.7% | -190.0% | ||
| Q3 25 | 22.4% | -176.3% | ||
| Q2 25 | 32.2% | -296.3% | ||
| Q1 25 | 28.2% | 13.6% | ||
| Q4 24 | 22.5% | -242.1% | ||
| Q3 24 | 26.0% | -256.6% | ||
| Q2 24 | 31.3% | -251.3% | ||
| Q1 24 | 23.9% | -408.8% |
净利率PEBKRGNX
| Q4 25 | 30.8% | -221.3% | ||
| Q3 25 | 17.2% | -208.3% | ||
| Q2 25 | 24.9% | -331.8% | ||
| Q1 25 | 21.8% | 6.8% | ||
| Q4 24 | 17.5% | -241.3% | ||
| Q3 24 | 19.3% | -246.3% | ||
| Q2 24 | 24.4% | -237.7% | ||
| Q1 24 | 19.9% | -405.4% |
每股收益（稀释后）PEBKRGNX
| Q4 25 | $1.21 | $-1.30 | ||
| Q3 25 | $0.67 | $-1.20 | ||
| Q2 25 | $0.95 | $-1.38 | ||
| Q1 25 | $0.79 | $0.12 | ||
| Q4 24 | $0.65 | $-0.99 | ||
| Q3 24 | $0.72 | $-1.17 | ||
| Q2 24 | $0.89 | $-1.05 | ||
| Q1 24 | $0.72 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $58.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $157.1M | $102.7M |
| 总资产 | $1.7B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PEBKRGNX
| Q4 25 | $58.1M | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | $59.3M | $234.7M | ||
| Q3 24 | $73.2M | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益PEBKRGNX
| Q4 25 | $157.1M | $102.7M | ||
| Q3 25 | $149.5M | $161.5M | ||
| Q2 25 | $144.0M | $213.7M | ||
| Q1 25 | $138.5M | $274.2M | ||
| Q4 24 | $130.6M | $259.7M | ||
| Q3 24 | $136.3M | $301.4M | ||
| Q2 24 | $124.3M | $348.3M | ||
| Q1 24 | $121.1M | $390.7M |
总资产PEBKRGNX
| Q4 25 | $1.7B | $453.0M | ||
| Q3 25 | $1.7B | $525.2M | ||
| Q2 25 | $1.7B | $581.0M | ||
| Q1 25 | $1.7B | $490.9M | ||
| Q4 24 | $1.7B | $466.0M | ||
| Q3 24 | $1.7B | $519.1M | ||
| Q2 24 | $1.7B | $569.4M | ||
| Q1 24 | $1.7B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $20.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 92.7% | -174.0% |
| 资本支出强度资本支出/营收 | 6.6% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.22× | — |
| 过去12个月自由现金流最近4个季度 | $34.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PEBKRGNX
| Q4 25 | $21.4M | $-52.3M | ||
| Q3 25 | $4.7M | $-56.0M | ||
| Q2 25 | $5.5M | $-49.3M | ||
| Q1 25 | $5.9M | $33.6M | ||
| Q4 24 | $20.6M | $-31.6M | ||
| Q3 24 | $4.9M | $-40.5M | ||
| Q2 24 | $6.7M | $-45.5M | ||
| Q1 24 | $3.7M | $-55.5M |
自由现金流PEBKRGNX
| Q4 25 | $20.0M | $-52.8M | ||
| Q3 25 | $4.4M | $-56.5M | ||
| Q2 25 | $5.4M | $-49.7M | ||
| Q1 25 | $5.2M | $32.6M | ||
| Q4 24 | $20.0M | $-32.7M | ||
| Q3 24 | $4.7M | $-40.9M | ||
| Q2 24 | $6.6M | $-46.0M | ||
| Q1 24 | $3.5M | $-56.0M |
自由现金流率PEBKRGNX
| Q4 25 | 92.7% | -174.0% | ||
| Q3 25 | 20.4% | -189.9% | ||
| Q2 25 | 25.9% | -232.8% | ||
| Q1 25 | 25.8% | 36.6% | ||
| Q4 24 | 98.0% | -154.2% | ||
| Q3 24 | 22.9% | -168.9% | ||
| Q2 24 | 32.7% | -206.2% | ||
| Q1 24 | 17.9% | -358.5% |
资本支出强度PEBKRGNX
| Q4 25 | 6.6% | 1.7% | ||
| Q3 25 | 1.5% | 1.7% | ||
| Q2 25 | 0.5% | 1.8% | ||
| Q1 25 | 3.8% | 1.2% | ||
| Q4 24 | 2.9% | 5.1% | ||
| Q3 24 | 1.0% | 1.3% | ||
| Q2 24 | 0.4% | 2.1% | ||
| Q1 24 | 0.6% | 3.6% |
现金转化率PEBKRGNX
| Q4 25 | 3.22× | — | ||
| Q3 25 | 1.27× | — | ||
| Q2 25 | 1.06× | — | ||
| Q1 25 | 1.36× | 5.53× | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 1.24× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 0.93× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PEBK
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
